Table 3.

Effects of IAV, E coli, or both IAV and E coli on Neutrophil Fas Ligand Expression and Neutrophil Release of Fas Ligand Into Supernatant

Assay Time (h) Control Buffer IAV E coliIAV + E coli
Neutrophil  FasL  20 7 ± 0.2  12 ± 13-150 10 ± 2  10 ± 2 
Neutrophil  FasL +  blocker  20  10 ± 1 10 ± 2  10 ± 2  8 ± 2  
Supernatant  FasL  3  0.14 ± 0.02  0.14 ± 0.01  0.16 ± 0.01 0.22 ± 0.053-150 
Supernatant  FasL  20  0.9 ± 0.2 1.36 ± 0.13-150 1.3 ± 0.2  1.3 ± 0.3 
Assay Time (h) Control Buffer IAV E coliIAV + E coli
Neutrophil  FasL  20 7 ± 0.2  12 ± 13-150 10 ± 2  10 ± 2 
Neutrophil  FasL +  blocker  20  10 ± 1 10 ± 2  10 ± 2  8 ± 2  
Supernatant  FasL  3  0.14 ± 0.02  0.14 ± 0.01  0.16 ± 0.01 0.22 ± 0.053-150 
Supernatant  FasL  20  0.9 ± 0.2 1.36 ± 0.13-150 1.3 ± 0.2  1.3 ± 0.3 

Results represent mean ± SEM of four experiments. Fas ligand expression on neutrophils and supernatant Fas ligand were measured with anti-FasL (C-20) polyclonal antibodies using flow cytometry or enzyme-linked immunosorbent assay (ELISA), respectively. Flow cytometry results are mean neutrophil fluorescence values, while ELISA results are OD450 values.

F3-150

Significant increase (P ≤ .05) as compared with neutrophil treated with buffer alone.

or Create an Account

Close Modal
Close Modal